Committee (IACUC) in the local interpretation and application of the law. is responsible for establishing guidelines and policies regulating animal use. reviewing protocols with surgical components. anesthesia/analgesia selection, and post-operative care and analgesia.
AYou will receive treatment with OPDIVO in a hospital or clinic, under the supervision of an experienced doctor. OPDIVO will be given to you as an infusion (a drip) into a vein (intravenously) over a period of 60 minutes, every 2 weeks.
Immune-mediated pneumonitis, defined as requiring use of corticosteroids and no clear alternate etiology, occurred in 2.2% (6/268) of patients receiving OPDIVO: one with Grade 3 and five with Grade 2 pneumonitis. The median time to onset for the six cases was 2.2 months (range: 25 days-3.5 months). In two patients, pneumonitis was diagnosed after discontinuation of OPDIVO for other reasons, and Grade 2 pneumonitis led to interruption or permanent discontinuation of OPDIVO in the remaining four patients.